In today’s article, the author shares what he considers to be “the best stocks in the best industries.” Those industries, in his view? Internet, footwear and specialty finance. For what he deems to be the best stocks from those three industries, CLICK HERE.
When it comes to a stock’s Relative Strength (RS) Rating, the author of today’s article notes that “History shows that the stocks that go on to make the biggest gains typically have an RS Rating north of 80 as they launch their biggest climbs.” The life sciences company he highlights just had its RS Rating upgraded from 80 to 89,…
While the biotech industry’s near-term potential is largely tied to the development of treatments for COVID-19, the author of today’s article notes that “The sector’s long-term potential remains solid due to the aging population and the rising cost of healthcare.” Against this backdrop, they proceed to highlight two biotech stocks that Wall Street analysts expect will see significant gains of…
At the mid-year point of 2021, what are the nation’s leading newsletter advisors’ favorite investment ideas for the remainder of the year? Today’s article reviews some of their top-performing picks from the beginning of the year and asks them for their mid-year updates. For ideas spanning biotech, cryptocurrency, electric vehicles, space exploration and more, CLICK HERE.
The price of Dogecoin – the current star of the cryptocurrency world – has fallen significantly from its recent highs. This has the author of today’s article advising that, “with the crypto bubble on shaky ground, aggressive investors might be wise to consider alternative growth vehicles soon” – and he highlights two biotech penny stocks to consider as those alternative…
Companies involved in stem cell therapies, cannabis overdose treatments, COVID-19 vaccinations and the treatment of lupus make up the four new biotech stocks to watch highlighted in today’s article, which also highlights a number of new stocks to watch in the mining sector (including those involved in “battery metals” such as graphite and lithium). For all of these new stocks…
Strong and sustained share price appreciation, solid upside potential, an outlook toward further growth, and approval from Wall Street analysts characterize the three “monster growth stocks” highlighted in today’s article – all of which are hovering at or near one-year highs and have the potential to reach new highs. For these three stocks – including a developmental-stage biopharmaceutical company focused…
“There are massive opportunities in the gene-editing space, but there are also a number of risks investors should know before jumping in,” advise the authors of today’s article. For a discussion of the risks associated with this exciting space that investors should keep in mind, CLICK HERE.
“A big, headline-grabbing company is not always your best bet, assuming you’re a shrewd investor seeking to maximize your profits,” advises the author of today’s article – and this may be especially true when it comes to biotech stocks. What two “size benefits” do smaller companies have – and why does the “size factor” work? CLICK HERE.
The pharmaceutical company featured in today’s article, known for its innovative drug pipeline, is a late-stage biotech focused on developing novel, oral, small-molecule drugs for rare and serious diseases. Having gained 153.8% over the past year and 60.1% year-to-date, is this a good biotech stock to own? For a look at the factors that could influence its performance in the near…